# India Sacroiliitis Treatment Market

> India Sacroiliitis Treatment Market Research Report By Type (Medications, Joint Injections, Joint Fusion, Radiofrequency Denervation, Electrical Stimulation) and By End-user (Hospitals, Clinics, Others) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 19.02%
- **2024:** $ 2,305.9 Million
- **2025:** $ 2,744.48 Million
- **2035:** $ 15,648 Million
- **Key Players:** AbbVie Inc (US), Amgen Inc (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Novartis AG (CH), Pfizer Inc (US), Roche Holding AG (CH), Sanofi S.A. (FR), UCB S.A. (BE)

**Report ID:** MRFR/HC/52194-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/india-sacroiliitis-treatment-market-53956

---

## Market Summary

## **India Sacroiliitis Treatment Market Overview**

As per MRFR analysis, the India Sacroiliitis Treatment Market Size was estimated at 1.56 (USD Billion) in 2023.The India Sacroiliitis Treatment Market is expected to grow from 1.84(USD Billion) in 2024 to 25.19 (USD Billion) by 2035. The India Sacroiliitis Treatment Market CAGR (growth rate) is expected to be around 26.826% during the forecast period (2025 - 2035)

**Key India Sacroiliitis Treatment Market Trends Highlighted**

The growing awareness of autoimmune disorders is causing a significant change in the Indian sacroiliitis treatment market. Important market drivers include the rising prevalence of diseases like ankylosing spondylitis and the expanding understanding that sacroiliitis plays a key role in chronic lower back pain.

Advanced imaging techniques and sacroiliitis-specific biochemical tests are becoming more widely used as a result of healthcare professionals' growing emphasis on the necessity for precise diagnosis and efficient treatment regimens for these illnesses. Furthermore, there are a lot of potential to investigate in digital health platforms and telemedicine for the treatment of sacroiliitis.

Patients in remote areas of India now have easier access to healthcare thanks to the COVID-19 epidemic, which has also spurred the use of virtual consultations. Biologic therapies, which provide more specialized treatment alternatives, are likewise becoming more and more popular. In India, the emphasis on customized medicine that meets the needs of each patient is also growing.

The market is growing because of the recent proactive efforts of patient advocacy groups and health organizations in India to increase awareness and offer assistance to those suffering with sacroiliitis. Numerous medical professionals are focusing on holistic treatment modalities, incorporating lifestyle management and physical therapy into traditional treatments.

India is therefore well-positioned to witness important advancements in the management and treatment of sacroiliitis, propelled by a changing healthcare environment and growing cooperation between healthcare players.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**India Sacroiliitis Treatment Market Drivers**

**Rising Prevalence of Inflammatory Diseases**

The incidence of inflammatory diseases, particularly ankylosing spondylitis which often leads to sacroiliitis, has been rising in India. The Ministry of Health and Family Welfare reports a noteworthy increase in the prevalence of autoimmune conditions, estimating that around 0.1-0.5% of the Indian population suffers from ankylosing spondylitis.

This translates to approximately 1.5-7.5 million cases in India alone. As a direct result, the demand for effective treatments in the India [Sacroiliitis Treatment Market](../../../reports/sacroiliitis-treatment-market-6590) is on the rise.

Organizations like the Indian Rheumatology Association are active in enhancing awareness about these diseases, driving diagnostic and treatment innovations in this market segment. The heightened focus on early diagnosis is likely to contribute significantly to market growth, especially as healthcare systems prioritize comprehensive treatment plans for patients.

**Advancements in Treatment Modalities**

The evolution of treatment options for sacroiliitis, including the introduction of biologics and advanced pain management therapies, is a major driver in the India Sacroiliitis Treatment Market. These innovative therapies are supported by evidence from clinical trials showing significant improvements in patient outcomes.

For instance, recent approvals from the Drug Controller General of India for new biologic agents have garnered interest from both investors and patients.

The access to innovative therapies is expected to expand treatment choices significantly, with leading pharmaceutical companies like Cipla and Dr. Reddy's Laboratories being pivotal in this transformation. As treatment landscapes evolve, the market is projected to grow, aligning with the changing dynamics of patient care.

**Increasing Awareness about Chronic Pain Management**

There is a growing recognition of the importance of chronic pain management among healthcare providers and patients in India, spurred by educational campaigns from institutions like the Indian Society for the Study of Pain. These initiatives have notably increased understanding about conditions like sacroiliitis, enabling patients to seek timely treatment.

According to the Indian Chapter of the International Pain Foundation, approximately 50-70 million people in India suffer from chronic pain, highlighting a substantial patient base that requires effective management strategies. This heightened awareness is expected to augment the India Sacroiliitis Treatment Market as more individuals are diagnosed and treated for sacroiliitis.

**India Sacroiliitis Treatment Market Segment Insights**

**Sacroiliitis Treatment Market Type Insights**

The India Sacroiliitis Treatment Market predominantly focuses on various treatment types to address the complexities associated with sacroiliitis, a condition primarily affecting the sacroiliac joints. Medications play a crucial role in managing inflammation and pain, with non-steroidal anti-inflammatory drugs being among the most common treatments.

They are often the first line of defense for patients, serving as foundational therapy before considering advanced options. Joint injections, particularly corticosteroid injections, are significant as they provide targeted relief, reducing inflammation directly in the affected joint. This method is often favored for its rapid efficacy in alleviating severe symptoms, demonstrating potential for improved patient outcomes.

Joint fusion is an important surgical option for chronic cases where other treatments have failed, offering a means of stabilizing the sacroiliac joint and potentially reducing pain significantly. This procedure has gained traction due to its ability to provide long-term relief for patients suffering from persistent discomfort.

Likewise, radiofrequency denervation is emerging as a minimally invasive alternative, aimed at disrupting pain signals from the affected nerve pathways, enabling significant pain management without the need for an extensive surgical procedure. This method is gradually being recognized for its effectiveness, particularly in patients looking to avoid traditional surgeries while still obtaining relief.

Electrical stimulation also represents an innovative avenue in the treatment landscape, utilizing neuromodulation techniques to alleviate pain through electrical impulses. This method is becoming increasingly popular as it is non-invasive and allows patients greater control over their pain management processes.

The integration of technological advancements in these treatment modalities reflects a growing trend towards personalized and patient-centric approaches within the India Sacroiliitis Treatment Market.

As demand for effective and innovative treatments continues to rise, these diverse options play a significant role in shaping the treatment landscape, ultimately catering to a wider patient demographic with varying needs and preferences.

The market is driven by an increasing prevalence of conditions linked to sacroiliitis, which can be attributed to factors such as lifestyle changes and the rising incidence of autoimmune diseases.

Government initiatives and increasing awareness about chronic pain management also contribute to this transformation, facilitating better access to treatments across the nation. Thus, the India Sacroiliitis Treatment Market is set to evolve, reflecting a shift towards comprehensive approaches that integrate various treatment types to enhance patient care.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Sacroiliitis Treatment Market****End-use****r Insights**

The India Sacroiliitis Treatment Market showcases a growing landscape, particularly when examining the End-user segment, which includes Hospitals, Clinics, and Others. Hospitals significantly contribute to the market due to their advanced medical facilities, specialized healthcare professionals, and comprehensive treatment options available for sacroiliitis.

This segment is crucial as it often handles complex cases that require sophisticated interventions, thereby driving a substantial portion of the overall market revenue. Clinics, on the other hand, present a more accessible alternative for patients seeking outpatient care and basic treatment modalities, making them a vital part of the overall treatment paradigm.

The rising prevalence of sacroiliitis in India, coupled with an increasing awareness of treatment options, drives patient traffic across both hospitals and clinics.

Additionally, the growing demand for specialized services and personalized care is pushing healthcare providers to enhance treatment protocols, creating opportunities for the Others segment, which comprises rehabilitation centers and home healthcare services. This segment is becoming increasingly relevant due to the rise in preferences for home-based care and rehabilitation approaches.

Overall, the dynamics within these End-user categories indicate robust potential for growth driven by increasing patient demands and advancements in treatment methodologies within the India Sacroiliitis Treatment Market.

**India Sacroiliitis Treatment Market Key Players and Competitive Insights**

The India Sacroiliitis Treatment Market has been characterized by a growing awareness of the condition and its management options among healthcare providers and patients. As the number of diagnosed cases of sacroiliitis continues to rise, driven by factors such as lifestyle changes and increased prevalence of autoimmune disorders, competition among pharmaceutical companies has intensified.

Market players are focusing on innovative treatment options, including biologics and conventional therapies, to address the varying needs of patients. The competitive landscape is marked by strategic partnerships, research collaborations, and the launch of novel drugs, aimed at improving therapeutic outcomes and enhancing patient quality of life.

With the continuing advancements in clinical research and technology, the ability to deliver effective treatment solutions in a timely manner has become imperative for companies operating within this niche market.

Bristol-Myers Squibb has established a robust presence in the India Sacroiliitis Treatment Market by offering a comprehensive range of therapies designed for autoimmune conditions, including sacroiliitis. Known for its commitment to research and development, the company has leveraged its expertise to introduce targeted and effective therapies that enhance patient outcomes.

Bristol-Myers Squibb's strengths in the Indian market stem from its extensive clinical trial programs and collaborations with healthcare professionals, ensuring that the latest treatment protocols are disseminated effectively.

Furthermore, their marketing strategies emphasize educating both physicians and patients about the disease and its management options, which aids in building trust and credibility among stakeholders. This strong market presence, compounded by a dedicated focus on innovation, positions Bristol-Myers Squibb as a notable competitor in the Indian sacroiliitis treatment domain.

Abbott Laboratories has made significant inroads into the India Sacroiliitis Treatment Market, particularly through its portfolio of advanced therapies and diagnostic solutions tailored to manage inflammatory conditions. The company’s strengths lie in its comprehensive approach, offering both pharmaceutical products and essential diagnostic tools that enable better patient assessment and management.

Abbott Laboratories is recognized for its strong distribution channels and established relationships with healthcare providers, which facilitate effective market penetration and accessibility of treatments. In addition to its core offerings, Abbott has engaged in potential mergers and acquisitions, allowing it to diversify its product portfolio and strengthen its competitive edge in India.

The company's focus on innovation, coupled with its commitment to enhancing patient care, reinforces its standing in the market as a key player in sacroiliitis management.

**Key Companies in the India Sacroiliitis Treatment Market Include**

- Bristol-Myers Squibb
- Abbott Laboratories
- Pfizer
- Sanofi
- Amgen
- Merck
- Dr. Reddy's Laboratories
- Johnson & Johnson
- Sun Pharmaceutical Industries
- GSK
- Boehringer Ingelheim
- AstraZeneca
- Cipla
- Novartis
- Mylan

**India Sacroiliitis Treatment****Market****Developments**

Recent developments in the India Sacroiliitis Treatment Market showcase increasing advancements and regulatory actions. Companies such as Bristol-Myers Squibb and Pfizer have intensified their Research and Development efforts, aiming to enhance their portfolios in autoimmune therapies.

As of September 2023, Amgen received a positive nod from regulatory authorities for a new biologic targeted at inflammatory diseases, which includes Sacroiliitis treatment options. Sanofi has also expanded its clinical trials in India, focusing on the efficacy of new medications in local demographics.

Notably, Dr. Reddy's Laboratories announced in August 2023 their collaboration with Johnson & Johnson to co-develop innovative therapies for chronic inflammatory conditions. In terms of market valuation, companies like Abbott Laboratories and Merck have seen incremental growth driven by increased demand for specialized treatments, reflecting a broader trend in India's healthcare sector.

Furthermore, AstraZeneca and GSK are exploring market entry strategies in India, targeting increased accessibility for patients. The last two to three years have witnessed significant advancements, with major pharmaceutical entities positioning themselves to meet rising patient needs in the face of growing lifestyle-related health issues, thereby influencing market dynamics positively.

**India Sacroiliitis Treatment Market Segmentation Insights**

**Sacroiliitis Treatment Market Type****Outlook**

- Medications
- Joint Injections
- Joint Fusion
- Radiofrequency Denervation
- Electrical Stimulation

**Sacroiliitis Treatment Market****End-use****r****Outlook**

- Hospitals
- Clinics
- Others

## Market Drivers

### Growing Geriatric Population

India's aging population is a critical factor influencing the sacroiliitis treatment market. As individuals age, the likelihood of developing musculoskeletal disorders, including sacroiliitis, increases. Projections indicate that by 2030, the geriatric population in India will reach approximately 300 million, creating a substantial demand for healthcare services, including treatments for sacroiliitis. This demographic shift suggests that healthcare providers will need to adapt their services to cater to the specific needs of older adults, potentially leading to an increase in the availability of treatment options. Consequently, the sacroiliitis treatment market may experience significant growth as healthcare systems respond to the needs of this expanding demographic.

### Increased Awareness and Education

There is a notable rise in awareness and education regarding sacroiliitis and related conditions among both healthcare professionals and the general public in India. Campaigns aimed at educating patients about the symptoms and treatment options for sacroiliitis are becoming more prevalent. This increased awareness is likely to lead to earlier diagnosis and treatment, which could positively impact the sacroiliitis treatment market. Furthermore, healthcare providers are increasingly focusing on training and educating their staff about the latest treatment protocols, which may enhance the quality of care provided to patients. As a result, the market may see a boost in demand for innovative treatment solutions.

### Advancements in Diagnostic Techniques

Innovations in diagnostic technologies are transforming the landscape of the sacroiliitis treatment market. Enhanced imaging techniques, such as MRI and CT scans, allow for earlier and more accurate diagnosis of sacroiliitis. This advancement is crucial, as timely diagnosis can lead to more effective treatment plans and improved patient outcomes. The Indian healthcare sector is increasingly adopting these technologies, which may lead to a rise in diagnosed cases of sacroiliitis. As a result, the demand for targeted therapies and treatment options is expected to grow, thereby driving the market forward. Moreover, the integration of artificial intelligence in diagnostics could further streamline the identification of sacroiliitis, potentially increasing the market's reach.

### Rising Prevalence of Autoimmune Disorders

The increasing incidence of autoimmune disorders in India is a significant driver for the sacroiliitis treatment market. Conditions such as ankylosing spondylitis, which often coexists with sacroiliitis, are becoming more prevalent. Recent studies indicate that approximately 0.5-1% of the Indian population may be affected by ankylosing spondylitis, leading to a corresponding rise in demand for effective treatment options. This trend suggests that healthcare providers are likely to focus more on diagnosing and treating sacroiliitis, thereby expanding the market. Furthermore, the growing awareness among patients regarding autoimmune diseases is prompting them to seek medical attention sooner, which could potentially increase the market size for sacroiliitis treatments in the coming years.

### Government Initiatives and Healthcare Policies

Government initiatives aimed at improving healthcare access and affordability are likely to play a pivotal role in the sacroiliitis treatment market. Policies that promote the availability of essential medications and treatments for chronic conditions can enhance patient access to necessary therapies. The Indian government has been implementing various health schemes to support patients with chronic illnesses, which may include those suffering from sacroiliitis. These initiatives could lead to increased funding for research and development in treatment options, thereby expanding the market. Additionally, public health campaigns that focus on chronic pain management may further elevate the profile of sacroiliitis treatment, encouraging more patients to seek care.

## Future Outlook

The [Sacroiliitis Treatment Market](https://www.marketresearchfuture.com/reports/sacroiliitis-treatment-market-6590) is projected to grow at a 19.02% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment options.

**New opportunities:**

- Development of telehealth platforms for remote consultations
- Investment in biologics and targeted therapies
- Expansion of patient education programs to enhance treatment adherence

By 2035, the market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type: Medications (Largest) vs. Joint Injections (Fastest-Growing)

The market for sacroiliitis treatment in India is primarily dominated by the medications segment, which captures the largest share among treatment types. This is followed by joint injections, a method that is increasingly being recognized for its effectiveness, thus gaining traction among healthcare providers and patients alike. Other segments such as joint fusion, radiofrequency denervation, and electrical stimulation, while vital, represent smaller portions of the market share, highlighting the strong preference for pharmaceutical interventions in treating sacroiliitis.

In terms of growth trends, the medications segment is bolstered by continuous advancements in drug formulations and increasing patient awareness regarding treatment options. On the other hand, joint injections are witnessing rapid adoption due to their ability to provide quick relief and reduce inflammation, making them an appealing option for patients. This growing propensity for non-invasive treatment options is contributing to the upward trajectory of joint injections, making them the fastest-growing segment in the market.

Medications: Dominant vs. Joint Injections: Emerging

Medications are the dominant force in the treatment landscape, owing to their established efficacy and broad acceptance among medical professionals. This segment includes a variety of anti-inflammatory and analgesic drugs that are critical in managing symptoms and improving the quality of life for patients. Conversely, joint injections, which involve administering corticosteroids or other agents directly into the sacroiliac joint, are emerging as a favored alternative. These injections provide rapid relief from pain and have fewer systemic effects compared to oral medications. The dual appeal of immediate relief and lower side effects positions joint injections as a significant growth area, catering to the evolving demands of the patient population seeking effective and minimally invasive treatment options.

### By End-User: Hospitals (Largest) vs. Clinics (Fastest-Growing)

The India sacroiliitis treatment market exhibits a varied distribution among end-user segments. Hospitals dominate the market, capturing the largest share due to their advanced facilities and comprehensive care capabilities. Clinics, while smaller in overall market share, are witnessing rapid growth driven by increased patient access to outpatient services and a shift towards personalized care.

Growth trends in the end-user segment are influenced by several factors including the rising prevalence of sacroiliitis and greater awareness among patients about treatment options. Increased investments in healthcare infrastructure and the establishment of specialized clinics are making clinics a faster-growing segment. As more individuals seek early diagnosis and treatment, the demand for services at clinics is expected to continue increasing, potentially altering market dynamics in the coming years.

Hospitals (Dominant) vs. Clinics (Emerging)

Hospitals represent the dominant force in the India sacroiliitis treatment market, equipped with state-of-the-art diagnostic and treatment technologies, and a wide range of multidisciplinary healthcare professionals. Their ability to provide comprehensive treatment plans and manage complex cases contributes to their strong position. In contrast, clinics are emerging as influential players, capitalizing on the trend of accessible healthcare. They often provide cost-effective treatment options and focus on patient-centric care, catering to the changing needs of patients who prefer non-hospital-based care. This dual structure of dominance and emergence within the segment reflects the evolving landscape of healthcare preferences in the market.

## Competitive Benchmarking

The sacroiliitis treatment market in India is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as AbbVie Inc (US), Johnson & Johnson (US), and Novartis AG (CH) are actively engaged in enhancing their market presence through various strategic initiatives. AbbVie Inc (US) has positioned itself as a leader in immunology, focusing on the development of novel therapies that target the underlying mechanisms of sacroiliitis. This strategic focus on innovation is indicative of a broader trend within the market, where companies are prioritizing research and development to meet the evolving needs of patients.The business tactics employed by these companies reflect a commitment to optimizing supply chains and localizing manufacturing processes. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Amgen Inc (US) and Pfizer Inc (US) suggests a trend towards consolidation, as these firms leverage their resources to enhance operational efficiencies and expand their product offerings.

In October  Johnson & Johnson (US) announced a strategic partnership with a leading Indian biotechnology firm to co-develop a new biologic therapy for sacroiliitis. This collaboration is expected to accelerate the development timeline and enhance access to innovative treatments for patients in India. The strategic importance of this partnership lies in its potential to combine local expertise with Johnson & Johnson's global resources, thereby fostering a more agile response to market demands.

In September  Novartis AG (CH) launched a new digital health platform aimed at improving patient engagement and adherence to treatment protocols for sacroiliitis. This initiative underscores the growing trend of digitalization within the healthcare sector, as companies seek to leverage technology to enhance patient outcomes. The strategic significance of this move is evident in its potential to not only improve treatment adherence but also to gather valuable data that can inform future product development.Furthermore, in August 2025, AbbVie Inc (US) expanded its clinical trial program for a novel JAK inhibitor specifically targeting sacroiliitis. This expansion reflects a commitment to advancing research in this therapeutic area and highlights the company's focus on addressing unmet medical needs. The strategic importance of this initiative is underscored by the increasing demand for effective treatment options in the Indian market.

As of November  current competitive trends indicate a shift towards digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are becoming increasingly vital, as companies recognize the need to collaborate in order to drive innovation and enhance patient care. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative therapies, and reliable supply chains, thereby reshaping the landscape of the sacroiliitis treatment market.

## Recent News & Developments

Recent developments in the India Sacroiliitis Treatment Market showcase increasing advancements and regulatory actions. Companies such as Bristol-Myers Squibb and Pfizer have intensified their Research and Development efforts, aiming to enhance their portfolios in autoimmune therapies.

As of September 2023, Amgen received a positive nod from regulatory authorities for a new biologic targeted at inflammatory diseases, which includes Sacroiliitis treatment options. Sanofi has also expanded its clinical trials in India, focusing on the efficacy of new medications in local demographics.

Notably, Dr. Reddy's Laboratories announced in August 2023 their collaboration with Johnson & Johnson to co-develop innovative therapies for chronic inflammatory conditions. In terms of market valuation, companies like Abbott Laboratories and Merck have seen incremental growth driven by increased demand for specialized treatments, reflecting a broader trend in India's healthcare sector.

Furthermore, AstraZeneca and GSK are exploring market entry strategies in India, targeting increased accessibility for patients. The last two to three years have witnessed significant advancements, with major pharmaceutical entities positioning themselves to meet rising patient needs in the face of growing lifestyle-related health issues, thereby influencing market dynamics positively.

## Report Scope

| MARKET SIZE 2024 | 2305.9(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 2744.48(USD Million) |
| MARKET SIZE 2035 | 15648.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 19.02% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | AbbVie Inc (US), Amgen Inc (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Novartis AG (CH), Pfizer Inc (US), Roche Holding AG (CH), Sanofi S.A. (FR), UCB S.A. (BE) |
| Segments Covered | Type, End-User |
| Key Market Opportunities | Emerging biologics and personalized therapies present growth opportunities in the sacroiliitis treatment market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition in the sacroiliitis treatment market. |
| Countries Covered | India |

## Frequently Asked Questions

**Q: What was the market valuation of the India sacroiliitis treatment market in 2024?**
A: The market valuation was $2305.9 Million in 2024.

**Q: What is the projected market valuation for the India sacroiliitis treatment market by 2035?**
A: The projected valuation for 2035 is $15648.0 Million.

**Q: What is the expected CAGR for the India sacroiliitis treatment market during the forecast period 2025 - 2035?**
A: The expected CAGR during this period is 19.02%.

**Q: Which companies are considered key players in the India sacroiliitis treatment market?**
A: Key players include AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Johnson & Johnson, Novartis AG, Pfizer Inc, Roche Holding AG, Sanofi S.A., and UCB S.A.

**Q: What segment had the highest valuation in the India sacroiliitis treatment market in 2024?**
A: Medications had the highest valuation at $4800.0 Million in 2024.

**Q: How much is the Joint Injections segment valued at in 2024?**
A: The Joint Injections segment was valued at $3200.0 Million in 2024.

**Q: What is the projected growth for the Electrical Stimulation segment by 2035?**
A: The Electrical Stimulation segment is expected to grow significantly, with a valuation of $3848.0 Million projected for 2035.

**Q: Which end-user segment had the highest valuation in 2024?**
A: The Hospitals segment had the highest valuation at $8000.0 Million in 2024.

**Q: What is the projected valuation for the Clinics segment by 2035?**
A: The Clinics segment is projected to reach a valuation of $5000.0 Million by 2035.

**Q: What does the market data suggest about the future of sacroiliitis treatment in India?**
A: The data suggests a robust growth trajectory, with a significant increase in market valuation expected by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-sacroiliitis-treatment-market-53956*